Related Experiment Videos
The genetics of malignant hyperthermia
1Department of Biological Sciences, University of Exeter, Washington-Singer Laboratories.
Journal of Medical Genetics
|February 1, 1993
Summary
Malignant hyperthermia susceptibility (MHS) is a major anesthesia risk. Genetic diagnosis is challenging, with only about 50% of families having mutations in the main candidate gene, limiting DNA testing for MHS.
Area of Science:
- Anesthesiology
- Human Genetics
- Pharmacogenomics
Background:
- Malignant hyperthermia susceptibility (MHS) is a primary cause of anesthesia-related mortality.
- Despite available treatments and invasive presymptomatic testing, MHS remains a significant clinical concern.
Purpose of the Study:
- To evaluate the potential for genetic diagnosis of malignant hyperthermia susceptibility.
- To assess the utility of DNA marker linkage and candidate gene mutation analysis for MHS diagnosis.
Main Methods:
- Investigated linkage of MHS to markers on chromosome 19q13.1-13.2.
- Identified and analyzed mutations in the skeletal muscle calcium release channel gene as a candidate gene for MHS.
Main Results:
- Linkage to chromosome 19q13.1-13.2 markers was identified in some MHS families.
- Mutations in the skeletal muscle calcium release channel gene likely account for MHS in approximately 50% of affected families, indicating genetic heterogeneity.
Conclusions:
- Genetic heterogeneity in MHS complicates presymptomatic diagnosis.
- DNA marker-based presymptomatic testing is currently feasible only for a subset of MHS families exhibiting linkage to specific chromosomal regions.